Continuing Medical Education Program - Purchase Exams
The purpose of The Medical Letter Continuing Medical Education Program is to provide a means for health care professionals (including physicians, physician assistants, nurse practitioners, and pharmacists) to keep up to date with new drugs that are approved by the FDA, as well as keep up with the recommended drug treatment for specific indications. Specifically, the content of The Medical Letter Continuing Medical Education Program covers the mechanisms of action, pharmacokinetics, clinical efficacy, adverse effects, drug interactions, and dosages of the drugs discussed. Participants are required to answer exam questions based on the content of The Medical Letter On Drugs and Therapeutics. Importantly, the objectives of developing the content on which the exam is based are to educate the participants, impact clinical practice, and improve patient outcomes. The Medical Letter's unbiased content is free of commercial influence and financial sponsorship. Our CME program is completely funded by fees paid by the exam participants. The Medical Letter Continuing Medical Education program is accredited by: ACCME, ABIM MOC, AAFP, and ACPE.

  The Medical Letter Individual Exams — Online Only
I would like to order the following Online Per Issue Individual Exams eligible for 2 credits each: $15
per exam
1513  Lixisenatide for Type 2 Diabetes; Pembrolizumab (Keytruda) for First-Line Treatment of Metastatic NSCLC; Inflectra - An Infliximab Biosimilar; Yosprala - A Combination of Aspirin and Omeprazole; Drug Interaction: Dabigatran (Pradaxa) and Statins (2 credits)   Expires 01/30/2018
1514  Drugs for Migraine (2 credits)   Expires 02/13/2018
1515  Auvi-Q Epinephrine Auto-Injector Returns; Crisaborole (Eucrisa) for Atopic Dermatitis; Anticoagulation of Elderly Patients at High Risk for Falls with Atrial Fibrillation; Extended-Release Calcifediol (Rayaldee) for Secondary Hyperparathyroidism; Kyleena - Another Hormonal IUD; Drug Interaction: Clopidogrel and PPIs (2 credits)
1516  Drugs for Hypertension (2 credits)
1517  Bezlotoxumab (Zinplava) for Prevention of Recurrent Clostridium difficile Infection; Nusinersen (Spinraza) for Spinal Muscular Atrophy; Exablate Neuro for Essential Tremor; Obeticholic Acid (Ocaliva) for Primary Biliary Cholangitis; Triferic for Iron Replacement (2 credits)
1518  Drugs for COPD (2 credits)
1519  Reduction of Cardiovascular Risk with Evolocumab (Repatha); Dupilumab (Dupixent) for Moderate to Severe Atopic Dermatitis; Plecanatide (Trulance) for Chronic Idiopathic Constipation; Arymo ER - A New Abuse-Deterrent Morphine Formulation; Pancreatitis with Eluxadoline (Viberzi) in Patients without a Gallbladder (2 credits)
1520  Drugs for Allergic Disorders (2 credits)
1521  Prescription Drug Prices in the US; Valbenazine (Ingrezza) for Tardive Dyskinesia; Oxymetazoline Cream (Rhofade) for Rosacea; FDA Warns Against Use of Codeine and Tramadol in Children and Breastfeeding Women (2 credits)
1522  Drugs for Opioid Use Disorder; Abuse-Deterrent Opioids (2 credits)
1523  Abaloparatide (Tymlos) for Postmenopausal Osteoporosis; Ocrelizumab (Ocrevus) for MS; Acetylcysteine (Cetylev) for Acetaminophen Overdose; Obalon Balloon System - Another Gastric Balloon for Weight Loss; Riboflavin (Photrexa) and Ultraviolet Light for Progressive Keratoconus (2 credits)
1524  Drugs for Sexually Transmitted Infections (2 credits)
1525  Drugs for Helicobacter pylori Infection; Brodalumab (Siliq) - Another IL-17A Antagonist for Psoriasis; Telotristat Ethyl (Xermelo) for Carcinoid Syndrome Diarrhea (2 credits)
1526  Drugs for Epilepsy (2 credits)
1527  Safety of Long-Term PPI Use; Sarilumab (Kevzara) for Rheumatoid Arthritis; Cardiovascular Effects of Some Antidiabetic Drugs (2 credits)
1528  Drugs for Asthma (2 credits)
1529  Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes; Prasterone (Intrarosa) for Dyspareunia; Safinamide (Xadago) for Parkinson's Disease; Deflazacort (Emflaza) for Duchenne Muscular Dystrophy (2 credits)
1530  Drugs for Cognitive Loss and Dementia; Tocilizumab (Actemra) for Giant Cell Arteritis (2 credits)
1531  Influenza Vaccine for 2017-2018; Mavyret and Vosevi - Two New Combinations for Chronic HCV Infection (2 credits)
1532  Drugs for Common Bacterial Infections in Adults; Tisagenlecleucel (Kymriah) for ALL (2 credits)
1533  Guselkumab (Tremfya) for Psoriasis; Edaravone (Radicava) for ALS; Lesinurad/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia; Cotempla XR-ODT - Another Long-Acting Methylphenidate for ADHD; Abemaciclib (Verzenio) - A Third CDK 4/6 Inhibitor for Breast Cancer (2 credits)
1534  Drugs for Parkinson's Disease (2 credits)
1535  Shingrix - An Adjuvanted, Recombinant Herpes Zoster Vaccine; Naldemedine (Symproic) for Opioid-Induced Constipation; Extended-Release Amantadine (Gocovri) for Dyskinesia in Parkinson's Disease; PARP Inhibitors for Ovarian Cancer (2 credits)
1536  Drugs for Postmenopausal Osteoporosis (2 credits)
1537  Antiviral Drugs for Seasonal Influenza 2017-2018; Betrixaban (Bevyxxa) for VTE Prophylaxis in Acute Medical Illness; Fiasp - Another Insulin Aspart Formulation for Diabetes; Triptorelin (Triptodur) for Central Precocious Puberty (2 credits)
1538  Drugs for GERD and Peptic Ulcer Disease (2 credits)